Zinc finger protein 433 (ZNF433)

Zinc finger protein 433 (ZNF433) is a member of the KRAB-ZFP transcription factor family, characterized by containing 12 C2H2-type zinc finger domains and an N-terminal KRAB domain which mediate transcriptional repression via chromatin remodeling[1]. ZNF433 is located on human chromosome 19 and primarily functions in the nucleus, where it regulates gene expression by binding sequence-specific regions of DNA and recruiting co-repressor complexes, mainly for transcription by RNA polymerase II[2][6][7]. ZNF433 is expressed at generally low basal levels in most normal tissues but is highly expressed in testicular tissue and, to a lesser extent, in hepatocytes and renal tubules[5]. In cancer biology, ZNF433 demonstrates a dual role: in some cancers (such as clear cell renal cell carcinoma), it acts as a tumor suppressor (downregulation correlates with advanced disease and poor prognosis), while in others (such as prostate cancer) its upregulation promotes tumor proliferation and migration via activation of specific oncogenic pathways, making it a therapeutic target candidate[1]. Additionally, ZNF433 is implicated in immune regulation and genomic stability, as it is linked to markers like TMB, MSI, and MMR deficiencies, and interacts with DNA methyltransferases and RNA modification factors[1]. There is growing evidence for the utility of ZNF433 as a diagnostic and prognostic biomarker in several malignancies, and its expression may predict sensitivity to targeted therapies, particularly MEK inhibitors[1]. No direct drugs or validated biochemical assays for clinical targeting of ZNF433 have yet been established, but its multifaceted regulatory role, disease associations, and impact on cancer prognosis and treatment response highlight its emerging therapeutic relevance[1][2][7].

Other names

ZNF433FLJ40981zinc finger protein 433

Not fully established for direct interacting drugs, but ZNF433 modulates MAPK/ERK pathway activity and may influence response to MEK inhibition